Association of Tumor-infiltrating Lymphocytes With Recurrence Score in Hormone Receptor-positive/HER2-negative Breast Cancer: Analysis of Four Prospective Studies
The clinical value of tumor infiltrating lymphocytes (TILs) in hormone receptor-positive (HR+)/HER2- breast cancer (BC) may be unearthed by focusing on more biologically aggressive tumors. Here we deepen and describe the correlation between RS and TILs, proposing an immuno-genomic model for HR+/HER2- BC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 27, 2023 Category: Cancer & Oncology Authors: Federica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, Valter Torri, Mario Giuliano, Fable Zustovich, Marta Mion, Carlo Alberto Tondini, Costanza De Rossi, Emilio Bria, Michela Franchi, Laura Merlini, Rosa Giannatiempo, Daniela Russo, Vittoria Foti Source Type: research
Association between hospital volume and outcomes in invasive ovarian cancer in Belgium: A population-based study
To study the association between hospital volume and outcomes in patients with invasive epithelial ovarian cancer (EOC). (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 27, 2023 Category: Cancer & Oncology Authors: Isabelle Savoye, Geert Silversmit, Jolyce Bourgeois, Cindy De Gendt, Roos Leroy, Hanna M Peacock, Sabine Stordeur, Philippe de Sutter, Fr édéric Goffin, Mathieu Luyckx, Guy Orye, Peter Van Dam, Toon Van Gorp, Leen Verleye Tags: Original Research Source Type: research
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: impact of clinicopathological factors and indirect comparison between treatment strategies
In non-small cell lung cancer (NSCLC), the immune checkpoint inhibitors (ICI) revolution is rapidly moving from metastatic to early-stage, however, the impact of clinicopathological variables and optimal treatment sequencing remain unclear. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Antonio Nuccio, Giuseppe Viscardi, Fabio Salomone, Alberto Servetto, Francesco Maria Venanzi, Silvia Teresa Riva, Sara Oresti, Francesca Ogliari, Mariagrazia Vigan ò, Alessandra Bulotta, Robert Cameron, Alessandra Esposito, Jacobi Hines, Roberto Bianco, Source Type: research
Immune checkpoint inhibitors in patients with cancers of unknown primary
Collectively, cancers of unknown primary (CUP) account for 2 –5% of all diagnosed cancers and are often associated with a poor prognosis [1]. Previous clinical trials using conventional chemotherapy in CUP patients did not yield the anticipated survival improvements [2]. Despite the transformative impact of precision medicine in various tumour types, addres sing CUP remained elusive despite exploring site-specific therapy and targeted therapies [3]. The former was guided by the traditional oncology approach of targeting the organ of origin however, a meta-analysis of the studies evaluating site-specific therapy did not s...
Source: European Journal of Cancer - October 25, 2023 Category: Cancer & Oncology Authors: Elie Rassy, Elias Karam, Sola Adeleke, Somto Okoli, Joao Galante, Stergios Boussios, Nicholas Pavlidis Tags: Editorial Source Type: research
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: a case-control study.
Estrogen receptor (ER) loss at metastatic relapse occurs in up to 20% of luminal-like primary breast tumors. Data about clinicopathological features associated with ER loss and its prognostic significance are limited. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 22, 2023 Category: Cancer & Oncology Authors: Stefania Morganti, Antonio Marra, Sara Gandini, Liliana Ascione, Mariia Ivanova, Konstantinos Venetis, Elham Sajjadi, Paola Zagami, Federica Giugliano, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Chiara Corti, Elisa De Camilli, Giusepp Tags: Original Research Source Type: research
Lymph node staging in grade 1 –2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
The aim of this study was to assess the disease-free survival (DFS) and overall survival (OS) of patients with grade 1 –2 endometrioid ovarian carcinoma apparently confined to the ovary, according to surgical staging. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 20, 2023 Category: Cancer & Oncology Authors: Nicol ò Bizzarri, Majdi Imterat, Robert Fruscio, Diana Giannarelli, Anna Myriam Perrone, Rosanna Mancari, Alexander Traut, Andrea Rosati, Andreas du Bois, Debora Ferrari, Pierandrea De Iaco, Raffaella Ergasti, Beyhan Ataseven, Tommaso Bianchi, Marco Di S Tags: Original research Source Type: research
Impact of Pembrolizumab Versus Chemotherapy on Health-Related Quality of Life in Patients With Metastatic Triple-Negative Breast Cancer: Results From the Phase 3 Randomized KEYNOTE-119 Study
We report results of prespecified health-related quality of life (HRQoL) analyses from KEYNOTE-119. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 20, 2023 Category: Cancer & Oncology Authors: Peter Schmid, Oleg Lipatov, Seock-Ah Im, Anthony Goncalves, Eva Mu ñoz-Couselo, Keun Seok Lee, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas Turner, Stefania Zambelli, Nadia Harbeck, Fabrice Andre, Rebecca Dent, Jaime A. Mejia, Xu Tags: Original Research Source Type: research
Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: is it worth?
The aim of this study was to assess the disease-free survival (DFS) and overall survival (OS) of patients with grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary, according to surgical staging. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 20, 2023 Category: Cancer & Oncology Authors: Nicol ò Bizzarri, Majdi Imterat, Robert Fruscio, Diana Giannarelli, Anna Myriam Perrone, Rosanna Mancari, Alexander Traut, Andrea Rosati, Andreas du Bois, Debora Ferrari, Pierandrea De Iaco, Raffaella Ergasti, Beyhan Ataseven, Tommaso Bianchi, Marco Di S Tags: Original Research Source Type: research
Response to letter: Re: Observational study investigating the level of support from a convolutional neural network in face and scalp lesions deemed diagnostically ‘unclear’ by dermatologists
To the Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 19, 2023 Category: Cancer & Oncology Authors: Katharina S. Kommoss, Holger A. Haenssle Tags: Letter to the editor Source Type: research
Response to Letter re: Observational study investigating the level of support from a convolutional neural network in face and scalp lesions deemed diagnostically ‘unclear’ by dermatologists
To the Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 19, 2023 Category: Cancer & Oncology Authors: K.S. Kommoss, H.A. Haenssle Source Type: research
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
Upfront anti-EGFR therapy represents the standard of care for patients with left-sided, MSS/pMMR, RAS and BRAF wild-type mCRC. Molecular “hyperselection” may maximize the therapeutic index of EGFR inhibition by detecting additional resistance alterations. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 19, 2023 Category: Cancer & Oncology Authors: Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, Filippo Ghelardi, Maria Caterina De Grandis, Marco Maria Germani, Giulia Barsotti, Vincenzo Formica, Giovanni Luca Frassineti, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato, Lorenzo Antonuzz Tags: Original Research Source Type: research
Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities
The number of systemic anticancer therapy (SACT) regimens has expanded rapidly over the last decade with the introduction of immunotherapy, small molecule targeted cancer medicines, and cell therapies. There is a need to ensure quality of SACT delivery across cancer services and systems in different resource settings to reduce morbidity, mortality, and detrimental economic impact at individual and systems level. Existing literature on SACT focuses on treatment efficacy with few studies on quality or how SACT is delivered within routine care in comparison to radiation and surgical oncology. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 18, 2023 Category: Cancer & Oncology Authors: Kari Leung, Megan McLeod, Julie Torode, Andr é Ilbawi, Jade Chakowa, Brian Bourbeau, Manju Sengar, Christopher M. Booth, Julie R. Gralow, Richard Sullivan, Ajay Aggarwal Tags: Review Source Type: research
Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies
The introduction of modern therapies improved the median survival of patients with metastatic melanoma (MM). Here, we determined the real-world impact of modern treatments on the long-term survival of MM. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 18, 2023 Category: Cancer & Oncology Authors: Aimilia Schina, Sidsel Pedersen, Anne-Louise Spenning, Olivia Kaas Laursen, Cecilia Pedersen, Charlotte Aaquist Haslund, Henrik Schmidt, Lars Bastholt, Inge Marie Svane, Eva Ellebaek, Marco Donia Tags: Original Research Source Type: research
Letter to the editor re: Observational study investigating the level of support from a convolutional neural network in face and scalp lesions deemed diagnostically ‘unclear’ by dermatologists.
To the Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 18, 2023 Category: Cancer & Oncology Authors: Julie Delyon, Beno ît Schmauch, Yannick Jacob, Maxime Battistella, Céleste Lebbé Tags: Letter to the Editor Source Type: research
Quality Indicators for Systemic Anti-cancer Therapy Services: A Systematic Review of Metrics used to Compare Quality Across Healthcare Facilities
The number of systemic anti-cancer therapy (SACT) regimens has expanded rapidly over the last decade with the introduction of immunotherapy, small molecule targeted cancer medicines, and cell therapies. There is a need to ensure quality of SACT delivery across cancer services and systems in different resource settings to reduce morbidity, mortality, and detrimental economic impact at individual and systems level. Existing literature on SACT focusses on treatment efficacy with few studies on quality or how SACT is delivered within routine care in comparison to radiation and surgical oncology. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 18, 2023 Category: Cancer & Oncology Authors: Kari Leung, Megan McLeod, Julie Torode, Andr é Ilbawi, Jade Chakowa, Brian Bourbeau, Manju Sengar, Christopher M. Booth, Julie R. Gralow, Richard Sullivan, Ajay Aggarwal Source Type: research
